{"entity":{"id":"nct07910942","kind":"trial","name":"A Phase 1 Trial of KAN-001 With Pembrolizumab, With or Without Chemotherapy, in Participants With PD-L1-Positive Non-Small Cell Lung Cancer","aka":[],"tldr":"A phase 1 trial of KAN-001 run by Kanvas Biosciences, not yet recruiting.","summary":"A Phase 1 Trial of KAN-001 With Pembrolizumab, With or Without Chemotherapy, in Participants With PD-L1-Positive Non-Small Cell Lung Cancer is a phase 1 interventional study registered as NCT07910942 by Kanvas Biosciences, with 40 participants planned, started 2026-11. Conditions recorded: Non-Small Cell Lung Cancer. Interventions recorded: KAN-001 and Pembrolizumab.","status":"planned","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT07910942","url":"https://clinicaltrials.gov/study/NCT07910942"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["kan-001"],"companies":["kanvas-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07910942","phase":"1","setting":"A Phase 1 Trial to Evaluate Safety, Tolerability, and Engraftment of KAN-001 in Combination With Pembrolizumab, With or Without Chemotherapy, in Participants With PD-L1-Positive Non-Small Cell Lung Cancer","sponsor":"Kanvas Biosciences","enrolled":40,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07910942/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"kan-001","kind":"drug","name":"KAN-001","route":"/drugs/kan-001/"}],"company":[{"id":"kanvas-biosciences","kind":"company","name":"Kanvas Biosciences","route":"/companies/kanvas-biosciences/"}]}}